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ABSTRACT
Background. To assess the outcome of and determine
prognostic factors for neck residue or recurrence of naso-
pharyngeal carcinoma (NPC) in patients treated with a
salvage neck dissection.
Materials and Methods. Over a 10-year period (from
January 1998 through December 2007) in a tertiary hos-
pital, we systematically reviewed the clinical charts of 355
patients with NPC who were diagnosed with neck residue
or recurrence of nasopharyngeal carcinoma, after radical
deﬁnitive radiotherapy with or without chemotherapy.
Results. The group with recurrent nodal disease consisted
of 285 patients (80.3%), while the group with residual nodal
diseaseincluded70patients(19.7%).Therewerenopatients
died of the surgery complications. Overall survival (OS),
disease-free survival (DFS), and disease-speciﬁc survival
(DSS) were 54.11, 35.01, and 55.59%, respectively, at
3-year, and 26.03, 22.65, and 27.84%, respectively, at
5-year. The local control rate in the neck was 70.92%
at 3 years and 60.98% at 5 years. For all the 3 survival
outcomes (OS, DFS, and DSS) and the local control rate of
disease in the neck, there were signiﬁcant differences
between the ‘‘residue group’’ and ‘‘recurrence group.’’
Conclusions. Radical neck dissection is proven to be safe
and effective in the treatment of the neck failure. Our study
has demonstrated that it may be possible to choose the
selective lymph node dissection for patients of the residue
group.
Nasopharyngeal carcinoma (NPC) is a relatively
uncommonmalignanttumor,distinctfrommalignanttumors
arisingfromtheotherheadandneckmucosalsitesintermsof
histopathological spectrum, clinical characteristic, and bio-
logicalbehavior.
1,2NPCisendemicinsouthernChinawhere
environmental factors, genetic predisposition, and Epstein-
Barr virus infection play an important part in its pathogen-
esis. Radiation therapy has been the standard treatment for
nasopharyngeal carcinomas, while chemotherapy in com-
bination with radiation therapy has been investigated in an
attempt to improve survival.
3 NPC has a high propensity to
metastasize to cervical lymph nodes, and enlarged neck
nodes are seen in approximately 75% of the patients.
4 There
is still some debate as to the optimal course of treatment for
NPC patients who have neck residue or recurrence. This
retrospective study may elucidate some important explana-
tions and information related to this condition.
MATERIALS AND METHODS
Patient Characteristics
The retrospective study included 355 nasopharyngeal
carcinoma patients, who had previously undergone radio-
therapy with or without chemotherapy, with previously
untreated neck residue or recurrence of nasopharyngeal
carcinomas with no evidence of distant metastases, treated
with salvage surgery (all patients underwent radical neck
dissection) in the Department of Head and Neck Surgery,
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through December 2007. Clinical, pathological, and
radiological data for these patients were reviewed and
retrospectively reclassiﬁed. There were 270 males (76.1%)
and 85 females (23.9%), their ages ranging from 15 to
79 years (median, 50 years). The time after the radiation
therapy with or without chemotherapy was from 2 to
480 months (median, 54 months). All the patients were
pathologically conﬁrmed as having neck metastasis by
ﬁne-needle aspiration cytology (FNAC) with the consent of
the patients. All the pathological samples were reviewed by
another independent pathologist in our hospital.
All patients diagnosed with NPC were treated with stan-
dard-course conventional radiotherapy. The typical regimen
consists of 65–78 Gy to the primary tumor, 60–70 Gy to
involved lymph nodes, and 50 Gy to the uninvolved neck
given in single daily fractions of 1.8–2.0 Gy, 5 days per
week, over 6–7 weeks. There were 87 patients who also
received chemotherapy during his or her treatment. All
patients required treatment to both sides of the neck.
Responses were evaluated according to the WHO criteria.
5
Tumor Characteristics
‘‘Recurrent nodal disease’’ was deﬁned as reappearance
of lymphadenopathy after initial complete regression of
nodal disease.
6 For patients suffering from nasopharyngeal
carcinoma, when their neck nodes do not regress com-
pletely by 3 months after completion of therapy, either
radiotherapy only or concomitant chemotherapy and
radiotherapy, there is likely to be residual disease in these
persistent lymph nodes.
7
The group with recurrent nodal disease consisted of 285
patients (80.3%), while the group with residual nodal dis-
ease consisted of 70 patients (19.7%). The general status of
the 2 groups is listed in Table 1.
Histopathologically, all the patients had WHO type 3
carcinomas, which are most prevalent in southern China.
8,9
According to the American Joint Committee on Cancer
Classiﬁcation staging system, tumors in 5 patients (1.4%)
were stage I, in 140 patients (39.4%) were stage II, in 164
patients (46.2%) of were stage III, and in 46 patients (13%)
stage IV.
10
Statistical Analysis
Overallsurvivalwasdeﬁnedasthetimefromdiagnosisto
death from any cause. Disease-free survival was deﬁned as
the time from diagnosis to local failure, nodal failure, sys-
temic failure, or death from any cause, whichever occurred
ﬁrst. Disease-speciﬁc survival was deﬁned as the time from
diagnosis to death from nasopharyngeal carcinoma. Patients
dying before evaluation of response were classiﬁed as
uncensored observations for overall survival, disease-free
survival,anddisease-speciﬁcsurvival.Thelocalcontrolrate
of disease in the neck was deﬁned as the patients free from
the disease in neck during the follow-up time.
Univariate analysis of survival estimations was per-
formed using the Kaplan–Meier method with log-rank test,
and multivariate analysis was performed using the Cox
proportional hazard model with forward stepwise selection.
Thecut-offpointofpatients’agewas40 years,asithasbeen
shown that this cut-off makes age a signiﬁcant prognostic
factor in NPC patients.
11,12 Epstein-Barr virus (EBV), a
humanherpesvirus,hasalsobeenstronglylinkedwithNPC.
It has been suggested that in situ hybridization of the EBV
encoded RNA (EBERs) is a more speciﬁc method for
detecting EBV in NPC than PCR, and EBERS may be rela-
tive to the prognosis of the patients.
13 Therefore, these
variables were taken into account in the current study. The
chi-square test was used to compare survival and local
control rate of the disease in the neck between the ‘‘residue
group’’ and ‘‘recurrence group.’’ In general, P values\.05
were considered statistically signiﬁcant.
RESULTS
Follow-Up
The majority of patients were followed regularly until
December 2008. All patients had been followed up for at
least12 months.Thefollow-uptimerangedfrom12 months
to 120 months, and the median time was 55 months.
Clinical Safety Outcome and Survival
In our study, no patients died of the surgery complica-
tions; 35 patients had chylous linkage in the neck, and 30
patients had incision infection.
TABLE 1 General status of 2 groups
Group
status
Residue group
(n = 70)
Recurrence group
(n = 285)
Total
(n = 355)
Gender
Male 63 207 270
Female 7 78 85
Age
B40 years 17 57 74
40 years 53 228 281
Stage of tumor
I2 3 5
II 32 108 140
III 25 139 164
IV 11 35 46
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and disease-speciﬁc survival (DSS) were 54.11, 35.01, and
55.59%, respectively, at 3 years; and 26.03, 22.65, and
27.84%, respectively, at 5 years. The local control rate of
disease in the neck was 70.92% at 3 years and 60.98% at
5 years (Table 2). During the follow-up time, 237 patients
died. Speciﬁcally, 15 patients died because of other disease
(heart attack, pneumonia, etc.), 39 patients died of bone
metastasis, 41 patients died of liver metastasis, 54 patients
died of lung metastasis, 36 patients died of neck recur-
rence, and 52 patients died of primary lesion recurrence.
Univariate analysis revealed involvement of a number of
different parameters to be signiﬁcant prognostic factors for
overall survival (Table 3), disease-speciﬁc survival
(Table 4), and for disease-free survival (Table 5). The
stage, EBERs, status of the lymph node (residue or recur-
rence), size of the lymph node, bilateral of cervical lymph
node relapse, invasion of cervical lymph node, and com-
plete surgical excision were evaluated as prognostic factors
for survival. The details of the pathological ﬁndings of the
neck dissection are listed in the Supplemental Table S1.
After the univariate analysis, we put all of the afore-
mentioned parameters into a Cox regression model. This
multivariate analysis revealed that the stage, EBERs,
lymph node status (residue or recurrence), invasion of
cervical lymph node, and completeness of the surgical
excision had a signiﬁcant correlation with the 3 survivals
(Table 6). Also the stage, EBERs, status of the lymph node
(residue or recurrence), invasion of cervical lymph node,
completeness of the surgical excision had a signiﬁcant
correlation with the local control rate of disease in the neck
(Table 6).
Differences Between ‘‘Residue Group’’
and ‘‘Recurrence Group’’
Statistical analysis demonstrated that there were signif-
icant differences of OS, DFS, DSS, and the local control
rate of the disease in the neck between the ‘‘residue group’’
and ‘‘recurrence group’’ (P\.05) (Table 2; Supplemental
Figs. S1–S4). In the residue group, 42 patients exhibited
persistent cervical lymph node during the therapy, and they
had only a single positive pathological lymph node after
neck dissection (Supplemental Table S1); it was the only
positive lymph node with the pathology diagnosis. These
42 patients had an increased chance of survival, as evi-
denced by 5-year OS, DFS, and DSS rates of 68.24, 45.30,
and 66.40%, respectively.
TABLE 2 Overall survival (OS), disease-free survival (DFS), disease-speciﬁc survival (DSS), and the local control rate of disease in the neck
Overall survival Disease-free survival Disease-speciﬁc survival Local control rate of the disease in the neck
3 years (%) 5 years (%) 3 years (%) 5 years (%) 3 years (%) 5 years (%) 3 years (%) 5 years (%)
All patients 54.11 26.03 35.01 22.65 55.59 27.84 70.92 60.98
Residue group 73.22 49.43 60.09 49.02 76.22 51.36 81.42 74.03
Recurrence group 48.91 19.93 30.11 16.23 49.91 21.65 64.32 55.81
P value of OS, DFS, DSS, and the local control rate of disease in the neck between the residue and recurrence group is .003, .002, .003, and .001,
respectively
TABLE 3 Summary of univariate analysis of prognostic factors for
overall survival
Parameter Cases observed Cases died P value
Gender
Male 270 183 .6293
Female 85 54
Age
B40 years 74 45 .2993
[40 years 281 192
Stage
I 5 2 .0001
II 140 65
III 164 125
IV 46 45
EBERs
Negative 113 44 .0001
Positive 242 193
Status of lymph node
Residue 70 36 .0001
Recurrence 285 201
Bilateral of cervical lymph nodes
No 330 216 .0195
Yes 25 21
Size of lymph node
B3 cm 225 126 .0001
3–6 cm 128 109
[6c m 2 2
Invasion
No 205 102 .0019
Yes 150 135
Complete surgical excision
No residual 326 208 .0001
Residual 29 29
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Recently, intensity-modulated radiotherapy (IMRT) has
been employed to deliver a therapeutic radiation dose to
the tumor in the nasopharynx while reducing the radiation
to nearby structures.
14 IMRT resolves the problem of dose
uncertainty and the target volume issue at lymphatic in the
neck, as it enables the primary tumor and the upper neck
nodes to be treated in 1 volume throughout, thus providing
excellent locoregional control of NPC.
15 However, there is
still a problem with how to approach failures associated
with the ﬁrst treatment for the neck lesion.
It is not uncommon for patients to present with recurrent
nodal disease after clinical response with no recurrence at
the primary site. The incidence of recurrent nodal disease is
7–18%.
16,17 Salvage surgery has an important role in the
treatment of recurrent nodal disease, although some centers
advocate re-irradiation with external beam or boost radio-
therapy, with reported cure rates of 14–28%.
18,19 This,
however, is associated with treatment-related morbidity,
secondary to cumulative radiation-induced injury. Radical
neck dissection is currently an accepted surgical manage-
ment for residual and recurrent nodal disease in patients
with NPC, with well-proven efﬁcacy and safety.
6,20,21 Inour
study, no patients died of the surgery complications. The
3-year and 5-year OS was 54.11 and 26.03%, respectively,
which is similar to previous reports.
22 As a result, it is rec-
ommended that salvage surgery is the optimal treatment
method for these patients.
When apatientpresentswithresidueorrecurrentcervical
lymph nodes after radiotherapy or chemoradiotherapy, fre-
quently there are 1 or 2 clinically palpable nodes. Even with
imaging studies, the number of lymph nodes detected is, in
general, only a few. Thus the extent of surgical resection
TABLE 4 Summary of univariate analysis of prognostic factors for
disease-speciﬁc survival
Parameter Cases observed Cases died P value
Gender
Male 270 171 .6080
Female 85 51
Age
B40 years 74 43 .4061
[40 years 281 179
Stage
I 5 2 .0001
II 140 54
III 164 123
IV 46 43
EBERs
Negative 113 36 .0001
Positive 242 186
Status of lymph node
Residue 70 33 .0001
Recurrence 285 189
Bilateral of cervical lymph nodes
No 330 201 .0069
Yes 25 21
Size of lymph node
B3 cm 225 114 .0001
3–6 cm 128 106
[6c m 2 2
Invasion
No 205 91 .0019
Yes 150 131
Complete surgical excision
No residual 326 193 .0001
Residual 29 29
TABLE 5 Summary of univariate analysis of prognostic factors for
disease-free survival
Parameter Cases observed Cases died P value
Gender
Male 270 191 .1202
Female 281 203
Age
B40 years 74 50 .5086
[40 years 281 203
Stage
I 5 2 .0001
II 140 71
III 164 136
IV 46 44
EBEV1
Negative 113 36 .0001
Positive 242 186
Status of lymph node
Residue 70 36 .0001
Recurrence 285 220
Bilateral of cervical lymph nodes
No 330 230 .0028
Yes 25 23
Size of lymph node
B3 cm 225 139 .0001
3–6 cm 128 112
6c m 2 2
Invasion
No 205 117 .0028
Yes 150 136
Complete surgical excision
No residual 326 224 .0001
Residual 29 29
236 L. Zhang et al.might range from excision of the enlarged node to selective
neck dissection, removing all the nodes within the levels of
where the lymph node was detected, to modiﬁed neck dis-
section, removing all the lymphatic tissue and lymph nodes
in the neck while preserving the nonlymphatic structures
such as the spinal accessory nerve, internal jugular vein, and
sternomastoid muscle, or to radical neck dissection. The
type of salvage surgery depends on the pathological
behavior of the metastatic nasopharyngeal carcinoma in the
lymph nodes. The pattern of lymph nodes affected by the
disease, their incidence of extracapsular spread, and the
involvement of the nonlymphatic structures in the vicinity
determine the extent of the salvage surgery. The patholog-
icalbehaviorofthenodalmetastaseswasreportedfollowing
a step serial sectioning of the specimens delivered after
radical neck dissection was performed for these patients,
regardless of whether the operation was performed for
persistent or recurrent cervical lymph nodes.
23
Since the ﬁrst study reported in 1992, the recommended
surgical salvage procedure for these patients suffering from
nasopharyngeal carcinoma who developed persistent or
recurrent cervical lymph nodes after radiotherapy or che-
moradiation should be radical neck dissection.
24 In our
retrospective study, all 355 patients had undergone the
radical neck dissection. However, when comparing the
‘‘residue group’’ and ‘‘recurrence group,’’ we found there
was a signiﬁcant difference in their survival rates (Sup-
plemental Fig. S1). This was especially true for those
patients who had just 1 persistent lymph node, as they
exhibited a signiﬁcantly improved prognosis. Meanwhile,
the local control rate of the disease in the neck was also
different between the 2 groups. So the residue group
patients have a better prognosis.
Based on the data presented here, we suggest that the
selective neck dissection, or at least the modiﬁed neck
dissection, may be the optimal treatment for these patients.
It is especially important to patients who have persistent
cervical lymph node during their therapy, as they may have
a longer survival time and better prognosis if following the
recommendations from our study. Further studies are nee-
ded to determine and conﬁrm which patients would beneﬁt
most from the selective neck dissection procedure.
Previous studies have suggested that younger patients
(age \40 years) and/or females may have a better prog-
nosis for NPC.
11,12 However, in our study these 2 factors
did not provide any ‘‘protection’’ for the neck failure
patients, suggesting that these factors may not be relevant
in selecting the type of neck dissection. It should be noted
that these results may only be pertinent for patients with
WHO type 3 carcinoma, which is more prevalent in
southern China.
8,9
Patients with lymph nodes measuring \30 mm had a
better prognosis than patients with larger nodes.
25,26 Of
note, the vast majority of the patient population in this study
had enlarged lymph nodes measured at B30 mm or
30–60 mm, and only a small percentage had nodes
[60 mm. It seems that this population had an extensive
locally advanced disease, with less extensive regional
lymph node involvement. Therefore, the size of the lymph
node could be an important factor for the choice of the type
of neck dissection. When the single residue lymph node has
affected a major structures in the neck, such as the internal
jugular vein, sternomastoid muscle, and so forth, selective
neck dissection is likely not the best option.
Recent studies have suggested that metastatic nodal
volume is an important prognostic factor in the treatment of
HNSCC.
27–30 These new methods could be helpful in the
decision-making process in selecting the optimal surgical
treatment for the residue patients. In addition, PET scans
may be helpful in preoperative conﬁrmation of the nodal
disease in preventing unnecessary neck dissection in the
clinical setting, but further studies are needed to assess the
efﬁcacy of this practice.
In conclusion, recurrent nodal disease in NPC patients
after curative radiotherapy is a challenging clinical prob-
lem, both diagnostically and therapeutically. Although the
safety and efﬁcacy of radical neck dissection are proven in
the treatment of recurrent disease, it is not without
TABLE 6 Cox regression model of multivariable analysis for overall survival (OS), disease-free survival (DFS), disease-speciﬁc survival (DSS)
and local control rate of disease in the neck
P value (OS) P value (DFS) P value (DSS) P value (local control rate)
Group .014 .021 .001 .024
Stage .000 .000 .000 .003
Bilateral .101 .146 .349 .378
Invasion .003 .004 .046 .001
Residual .000 .000 .000 .000
EBERs .000 .000 .000 .000
Size .978 .768 .982 .550
Group residue group and recurrence group, Invasion surgical specimens were invasion of the tissue or organ outside the lymph node, Bilateral
patients have bilateral neck failed after ﬁrst therapy
Salvage Surgery for Neck Residue or Recurrence of NPC 237morbidity. Our study has demonstrated that patients with a
persistent cervical lymph node (persistent during the ther-
apy and after neck dissection) and with only a single
positive pathological lymph node may beneﬁt from the
selective lymph node dissection.
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